IRCT20210831052350N1招募中3 期
Comparison the effect deferasirox swallow form (Jadenu®) with deferasirox granule (Exjade®) in reduce of serum ferritin in patients with major and intermedia beta thalassemia
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 years 至 50 years（—）
- 性别
- All
入选标准
- •Age over 2 years
- •Patients diagnosed with thalassemia major and intermedia
- •Having conscious satisfaction
- •Serum ferritin above 1000 µg / m
排除标准
- •Existence of contraindications to the studied drugs (Exjade®) and (Jadenu®)
- •Patients with GFR ?40 mL / min / 1.73 m2
- •Patients with stunted growth
- •Patients at high risk for myelodysplasia syndrome (MDS)
- •Advanced cancer
- •Platelets below 50 x 109 / L
- •Patients with knowledge of sensitivity to drugs of the defrazirox group
- •Patients with liver failure
- •Patients with gastrointestinal bleeding
- •Patients with renal insufficiency
- •Simultaneous use of other iron chelators
研究者
相似试验
已完成
2 期
Effect of Osveral on iron overload in beta thalassemia major patients.beta thalassemia.beta thalassemiaIRCT2015102524679N2Investigator69
招募中
不适用
Efficay comparison two oral chelators combination in patients with beta-thalassemiaIRCT20160310026998N7Tabriz University of Medical Sciences54
尚未招募
4 期
Bioequivalence Study of 500 mg Deferasirox Dispersible Tablets in Healthy Thai under Fasting ConditioBioequivalence studyTCTR20170222005Research and Development36
已完成
3 期
Compare the efficacy of combination therapy of Deferasirox and Deferiprone in reducing iron load in patients with transfusion-Dependent ß-Thalassemia.transfusion-Dependent ß-Thalassemia.Beta thalassemiaIRCT20190106042262N1Esfahan University of Medical Sciences108
进行中（未招募）
不适用
Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload - NDMedDRA version: 6.1Level: HLGTClassification code 10022958thalassemiaEUCTR2006-006838-17-ITOVARTIS FARMA8